School of Basic Medicine, Shanxi University of Chinese Medicine, Taiyuan 030001, Shanxi, China.
School of Management, Shanxi Medical University, Taiyuan 030001, Shanxi, China; Shanxi Medical Health Media Group Co.,Ltd, Taiyuan 030001, Shanxi, China.
Osteoarthritis Cartilage. 2019 May;27(5):726-736. doi: 10.1016/j.joca.2018.10.009. Epub 2018 Nov 2.
This study was design to examine the diagnostic performance of cartilage oligomeric matrix protein (COMP), C-terminal cross-linking telopeptide of type II collagen (CTX-II), and matrix metalloproteinase-3 (MMP-3) as biomarker for knee and hip OA.
Systematic search on multiple databases was completed in January 2018 using certain keywords. COMP, CTX-II, MMP-3 levels in knee and hip OA patients and healthy individuals were collected and calculated. Differences between subgroups were expressed as standardized mean differences (SMD). Subgroup analyses were performed to compare COMP, CTX-II, and MMP-3 performance between measuring sources, genders, large and small sample size and diagnostic criteria for OA patients.
A moderate performance of COMP in distinguishing between knee (SMD: 0.68; 95% confidence intervals (CI): 0.43-0.93; P < 0.0001) or hip (SMD: 0.25; 95% CI, 0.10, 0.40; P = 0.0008) OA patients and controls were found. CTX-II showed a moderated standardised mean differences (SMD) of 0.48 (95% CI, 0.32, 0.64; P < 0.0001) in the detection of knee OA and a large SMD of 0.76 (95% CI, 0.09, 1.42; P = 0.03) in diagnosing hip OA. A small SMD of 0.32 (95% CI, -0.03, 0.67; P = 0.07) was found for MMP-3 performance and the results did not reach statistic significance. Progression study revealed potential effectiveness of serum COMP in predicting OA progression. Subgroup analysis showed that serum COMP and urinary CTX-II performed better in male than female. Study size and diagnostic criteria did not significantly influence the pooled SMD, but they might be the sources of heterogeneity among studies.
The overall results indicates that serum COMP and urinary CTX-II can distinguish between knee or hip OA patients and control subjects. Serum COMP is effective in predicting OA progression.Further researches with rigorous study design and a larger sample size are required to validate our findings.
本研究旨在探讨软骨寡聚基质蛋白（COMP）、Ⅱ型胶原 C 末端交联肽（CTX-II）和基质金属蛋白酶-3（MMP-3）作为膝关节和髋关节骨关节炎生物标志物的诊断性能。
2018 年 1 月，我们通过多个数据库进行了系统检索，使用了特定的关键词。收集并计算了膝关节和髋关节骨关节炎患者和健康个体的 COMP、CTX-II 和 MMP-3 水平。亚组间的差异用标准化均数差（SMD）表示。进行了亚组分析，以比较 COMP、CTX-II 和 MMP-3 在测量来源、性别、样本量大小和骨关节炎患者的诊断标准方面的表现。
我们发现 COMP 在区分膝关节（SMD：0.68；95%置信区间（CI）：0.43-0.93；P<0.0001）或髋关节（SMD：0.25；95%CI，0.10，0.40；P=0.0008）骨关节炎患者和对照组方面具有中等表现。CTX-II 在检测膝关节骨关节炎时显示出中等标准均数差（SMD）0.48（95%CI，0.32，0.64；P<0.0001），在诊断髋关节骨关节炎时显示出较大的 SMD 0.76（95%CI，0.09，1.42；P=0.03）。MMP-3 表现的 SMD 较小，为 0.32（95%CI，-0.03，0.67；P=0.07），结果无统计学意义。进展研究表明血清 COMP 具有预测 OA 进展的潜在效果。亚组分析表明，血清 COMP 和尿 CTX-II 在男性中的表现优于女性。研究规模和诊断标准并没有显著影响汇总 SMD，但它们可能是研究间异质性的来源。
总体结果表明，血清 COMP 和尿 CTX-II 可区分膝关节或髋关节骨关节炎患者和对照组。血清 COMP 可有效预测 OA 进展。需要进一步进行设计严谨、样本量更大的研究来验证我们的发现。
Zotero 插件